150 related articles for article (PubMed ID: 7831532)
1. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity.
Zafrani B; Leroyer A; Fourquet A; Laurent M; Trophilme D; Validire P; Sastre-Garau X
Semin Diagn Pathol; 1994 Aug; 11(3):208-14. PubMed ID: 7831532
[TBL] [Abstract][Full Text] [Related]
2. The classification of ductal carcinoma in situ and its association with biological markers.
Bobrow LG; Happerfield LC; Gregory WM; Springall RD; Millis RR
Semin Diagn Pathol; 1994 Aug; 11(3):199-207. PubMed ID: 7831531
[TBL] [Abstract][Full Text] [Related]
3. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
[TBL] [Abstract][Full Text] [Related]
4. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
[TBL] [Abstract][Full Text] [Related]
5. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
6. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
8. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
Wilbur DC; Barrows GH
Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
[TBL] [Abstract][Full Text] [Related]
9. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers.
Moreno A; Lloveras B; Figueras A; Escobedo A; Ramon JM; Sierra A; Fabra A
Mod Pathol; 1997 Nov; 10(11):1088-92. PubMed ID: 9388058
[TBL] [Abstract][Full Text] [Related]
10. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
[TBL] [Abstract][Full Text] [Related]
11. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
12. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
[TBL] [Abstract][Full Text] [Related]
13. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
[TBL] [Abstract][Full Text] [Related]
14. [Clinicopathologic features and treatment of ductal carcinoma in situ of the breast].
Zhou L; Wang Y; Song X; Du JW; Pei F; Huang LP; Wang WY; Liu ZB; Pan RQ
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3035-8. PubMed ID: 16324401
[TBL] [Abstract][Full Text] [Related]
15. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu.
Diallo R; Rody A; Jackisch C; Ting E; Schaefer KL; Kissler S; Karn T; Geddert H; Engels K; Kaufmann M; Gabbert HE; Shroyer KR; Poremba C
Hum Pathol; 2006 Feb; 37(2):205-11. PubMed ID: 16426921
[TBL] [Abstract][Full Text] [Related]
16. Expression of p53 protein in infiltrating and in-situ breast carcinomas.
Walker RA; Dearing SJ; Lane DP; Varley JM
J Pathol; 1991 Nov; 165(3):203-11. PubMed ID: 1684809
[TBL] [Abstract][Full Text] [Related]
17. Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers.
Bobrow LG; Happerfield LC; Gregory WM; Millis RR
J Pathol; 1995 Aug; 176(4):333-41. PubMed ID: 7562248
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
19. bcl-2 expression in the spectrum of preinvasive breast lesions.
Siziopikou KP; Prioleau JE; Harris JR; Schnitt SJ
Cancer; 1996 Feb; 77(3):499-506. PubMed ID: 8630957
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]